Allogene Therapeutics Inc

Following a Stage 1 consolidation attempt after a terminal decline, the stock exhibits a repaired EMA regime yet remains under an active Lower Highs & Lower Lows pattern, reinforcing a medium-term bearish bias. In the short term, price is tightly tracking above the rising 9/21-EMA zone without a clear rejection signal, arguing for patience and deferred execution until a more decisive breakdown or EMA rejection occurs.

• ↑58.3% MRD clearance vs 16.7% control in Alpha-3 trial signals strong efficacy
• ↑Analyst median target of $12.46 implies ~520% upside
• ↓Q1 net loss of $42.6M (18¢/share) highlights profitability gap